STAGE IV LUNG CANCER AJCC V8

This early-stage study is testing a new combination treatment for advanced non-small cell lung cancer that has spread or returned. Researchers are combining a drug made from vitamin A (ATRA) with an immunotherapy drug (atezolizumab) to see if it is safe and to find the best dose.…

This study is testing whether two new drug approaches work better than standard chemotherapy for people with a specific type of advanced lung cancer that has worsened after initial treatment. About 117 participants will be randomly assigned to receive either a pill called cabozan…

This trial is testing a combination of three drugs (niraparib, temozolomide, and atezolizumab) to see if they work better together to control advanced cancers, especially a type called extensive-stage small cell lung cancer. The study first finds a safe dose, then compares the th…

This early-stage trial is testing a new way to give an immunotherapy drug called nivolumab to patients with melanoma or lung cancer that has spread to the membranes surrounding the brain and spinal cord. The goal is to see if giving the drug directly into the spinal fluid, along …

This study is for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation). It tests if taking the targeted drug osimertinib for 6-12 weeks, then adding focused radiation therapy or surgery to remaining tumors, works better at keeping the…

This early-stage study aims to find the safest and most effective dose of a new drug, M6620, when given with the chemotherapy drug irinotecan. It is for adults with advanced solid tumors, like certain colorectal, pancreatic, or lung cancers, that have spread or cannot be removed …

This early-stage trial is testing the safety and best dose of a two-drug combination for people with a specific type of advanced lung cancer. The study is for adults whose EGFR-mutant non-small cell lung cancer has continued to grow despite prior targeted therapy. Researchers wan…

This study is for people with advanced non-small cell lung cancer that has low levels of a marker called PD-L1. It compares the standard immunotherapy treatment (with or without chemo) to the same treatment plus a short course of radiation. The goal is to see if adding radiation …

This study is testing whether a lung cancer immunotherapy drug can be safely and effectively given at home by a visiting nurse, with most doctor visits done remotely via video call. It involves patients with non-small cell lung cancer who are eligible for the drug atezolizumab. T…

This study is testing whether adding a new drug called berzosertib to a standard three-drug treatment works better for people with advanced squamous cell lung cancer. It aims to control the cancer's growth and extend the time patients live without their disease getting worse. The…

This study aims to find the best next treatment for people with advanced ALK-positive non-small cell lung cancer that has worsened after initial targeted therapy. Doctors test a fresh tumor sample to identify specific genetic changes causing drug resistance, then match each patie…

This study is testing a new, faster way to give radiation after surgery for non-small cell lung cancer. Instead of weeks of daily treatments, doctors give one powerful, highly focused dose to try to kill any leftover cancer cells while aiming to spare healthy lung tissue. The mai…

This early-stage study is testing whether adding an experimental drug called minnelide to an existing lung cancer medication (osimertinib) is safe and might help patients whose cancer has continued to grow. The trial is for adults with advanced non-small cell lung cancer that has…

This early study is testing a two-part treatment for advanced non-small cell lung cancer with a specific genetic change (ALK). First, patients take a targeted drug (brigatinib) to shrink tumors. Then, they receive focused radiation or surgery to try to eliminate any remaining can…

This study is comparing two standard ways to treat small lung tumors: a minimally invasive procedure that uses microwave energy to heat and destroy the tumor, and a small surgery to cut it out. Researchers want to see which method is safer, more effective at keeping the cancer fr…

This study is testing whether combining two drugs, atezolizumab and cobimetinib, can help control advanced non-small cell lung cancer that has spread or returned and has stopped responding to a common type of immunotherapy. The trial aims to see if this combination can shrink tum…

This study is testing if adding a drug called bevacizumab to a standard lung cancer drug (osimertinib) works better to control cancer that has spread to the brain. It is for adults with a specific type of advanced lung cancer (EGFR-positive non-small cell lung cancer) who have no…

This study is for people with stage IV non-small cell lung cancer. It tests if adding local treatments like surgery or radiation to a two-drug immunotherapy regimen helps patients live longer than immunotherapy alone. The trial enrolled 339 patients who had not progressed after a…

This early-stage trial is testing a new drug called BAY 1895344, given alongside standard chemotherapy drugs, in people with advanced solid tumors that have spread. The main goal is to find the safest and most effective dose of this combination. Researchers are especially interes…

This study is testing if adding a new drug called pevonedistat to two standard chemotherapy drugs (carboplatin and paclitaxel) works better for people with advanced non-small cell lung cancer. It is for adults whose cancer has gotten worse after treatment with immunotherapy. The …

This early-stage study is testing a new combination of two drugs, sonidegib and pembrolizumab, for people with advanced solid tumors that have spread. The main goals are to find the safest dose of the combination and see if it helps shrink or control the cancer. The study is enro…

This is a small, early-stage safety study testing a combination of two cancer drugs, nivolumab and cabozantinib, in people living with HIV who have advanced solid tumors. The main goal is to see if the two-drug combination is safe and tolerable for this specific patient group. Re…

This is a first-in-human study to find a safe dose of an experimental pill called WSD0922-FU for people with aggressive brain tumors or lung cancer that has spread to the brain. The pill is designed to block a specific protein (EGFR) that drives these cancers and may be able to r…

This trial is testing whether combining an experimental cancer vaccine (CIMAvax) with approved immunotherapy drugs (nivolumab or pembrolizumab) is safe and more effective for treating advanced non-small cell lung cancer or squamous head and neck cancer. The study aims to find the…

This is an early-stage trial testing a combination of two oral drugs, sapanisertib and telaglenastat, for patients with advanced non-small cell lung cancer that has spread and progressed after standard treatments. The main goals are to find the safest dose of the drug combination…

This early-stage study is testing a new type of cell therapy for people with advanced non-small cell lung cancer that has spread and no longer responds to standard immunotherapy. Researchers are giving patients specially modified immune cells (called NK cells) taken from umbilica…

This early-stage trial is testing a combination of two oral drugs, osimertinib and telaglenastat, for adults with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation) and has stopped responding to standard targeted therapy. The main goals are to …

This early-stage study is testing the safety and best dose of an experimental drug called berzosertib when given alongside standard whole-brain radiation therapy. It involves patients with lung cancer that has spread to the brain. The hope is that combining the drug with radiatio…

This study is testing an oral drug called selpercatinib for people with advanced non-small cell lung cancer that has a specific genetic change called a RET fusion. The goal is to see how well the drug shrinks tumors and controls the cancer by blocking the abnormal protein driving…

This study tests whether a precise form of radiation called stereotactic radiosurgery (SRS) can control lung cancer that has spread to the brain while better preserving patients' memory and thinking abilities. It compares SRS, which targets only the tumors, to standard whole-brai…

This trial is testing whether adding a new drug called LY3295668 to an existing lung cancer drug (osimertinib) can help control cancer that has stopped responding to standard treatment. It involves 32 adults with a specific type of advanced lung cancer (EGFR-mutant non-small cell…

This study is testing a combination of two drugs, trametinib and pembrolizumab, for people with advanced non-small cell lung cancer that has come back or spread after previous treatments. The goal is to see if the drugs work better together to control the cancer and to find the s…

This large, late-stage trial aims to find the best way to combine immunotherapy and chemotherapy for patients with advanced non-squamous lung cancer. It will compare starting with immunotherapy alone versus starting with both treatments together, and test different approaches if …

This study is testing a new combination of treatments for people with extensive-stage small cell lung cancer who haven't had treatment yet. It combines a targeted drug (olaparib), an immunotherapy drug (durvalumab), standard chemotherapy, and radiation. The goal is to see if this…

This early-phase study is testing a combination of two drugs, brigatinib and bevacizumab, for patients with a specific type of advanced lung cancer (ALK-positive) that has worsened despite prior targeted therapy. The main goals are to find the safest dose and understand the side …

This study is testing a new combination of three drugs for people with advanced non-small cell lung cancer that has spread or come back after standard treatments failed. The goal is to see if mixing an immunotherapy drug, a drug that blocks tumor blood supply, and a chemotherapy …

This early-stage study is testing a combination of four drugs for people with a specific type of advanced lung cancer (ALK-positive). The main goals are to find the safest dose of the new drug, ensartinib, when given with three other cancer drugs, and to see what side effects occ…

This study is testing an experimental pill called AMG 510 for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. The pill is designed to block this specific mutation, which can drive cancer growth, in patients whose cancer has wor…

This study is testing whether a special program led by nurses can help people with advanced lung or gynecologic cancer cope with intense fears about their illness getting worse. Participants will have five short video sessions over six weeks to learn worry management skills, set …

This study is testing a simple, easy-to-understand conversation tool designed to help people with non-small cell lung cancer. The tool aims to improve how patients and doctors talk about treatment options, making the decision-making process clearer and less stressful. Researchers…

This study is testing an online support program designed to help women with lung cancer feel better emotionally and manage their symptoms. Participants are assigned to either a group learning mindfulness and coping skills or a group receiving educational information about lung ca…

This study is testing whether a medication called anamorelin can help improve appetite and prevent weight loss in people with advanced lung cancer who have poor appetite. Researchers will compare anamorelin against a placebo (inactive pill) in 25 patients over 9 weeks. The study …

This study aims to see if doctors can reliably measure the amount of a common chemotherapy drug (paclitaxel) in a patient's blood. The goal is to learn if tracking these levels can help find the right dose to fight cancer while reducing a severe side effect: nerve damage that cau…

This study is testing whether a short educational video can help patients with advanced cancer better understand tumor genomic testing. It involves 243 adults with metastatic breast or lung cancer who are already scheduled for this type of testing. Researchers will measure if wat…